Hormone-refractory prostate cancer

7 trials 5 recruiting MedDRA PT
7 Registered trials
5 Recruiting
6 Unique sponsors
10 Unique IMPs
7 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
L Oncology (ATC L) 2
V Various (ATC V) 2
H Endocrinology (ATC H) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 6 substances
Radiopharmaceutical 2 substances
Taxane 1 substance
Corticosteroid 1 substance
Phase III: 3 Phase I/II: 1 Phase I: 3

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase III

3 trials
  • AstraZeneca AB Commercial
    CAPIVASERTIB; DOCETAXEL
    2023-504996-26-00 8 countries 2022 n=424
    Ended
  • Curium Pet France Commercial
    LUTETIUM (177LU) ZADAVOTIDE GURAXETAN; PIFLUFOLASTAT (18F)
    2022-501493-19-00 3 countries 2023 n=150
    Ended
  • Janssen - Cilag International Commercial
    JNJ-78278343
    2025-520927-26-00 7 countries 2025 n=247
    Recruiting

Phase I/II

1 trial
  • Novartis Pharma AG Commercial
    ABIRATERONE; AMO959; ENZALUTAMIDE; LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; PREDNISONE
    2025-521859-23-00 4 countries 2026 n=73
    Recruiting

Phase I

3 trials
  • Daiichi Sankyo Inc. Commercial
    IMP not specified
    2025-521886-28-00 1 country 2026 n=15
    Recruiting
  • Janssen - Cilag International Commercial
    IMP not specified
    2023-504063-17-00 2 countries 2024 n=71
    Recruiting
  • Vir Biotechnology Inc. Commercial
    IMP not specified
    2023-503495-24-00 1 country 2023 n=75
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Janssen - Cilag International Commercial 2 Phase I, Phase III 2
Daiichi Sankyo Inc. Commercial 1 Phase I 1
Vir Biotechnology Inc. Commercial 1 Phase I 1
AstraZeneca AB Commercial 1 Phase III 0
Curium Pet France Commercial 1 Phase III 0
Novartis Pharma AG Commercial 1 Phase I/II 1
New trials by year
2022
1
2023
2
2024
1
2025
1
2026
2
← All indication landscapes